These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 29311118)
21. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Rader J; Russell MR; Hart LS; Nakazawa MS; Belcastro LT; Martinez D; Li Y; Carpenter EL; Attiyeh EF; Diskin SJ; Kim S; Parasuraman S; Caponigro G; Schnepp RW; Wood AC; Pawel B; Cole KA; Maris JM Clin Cancer Res; 2013 Nov; 19(22):6173-82. PubMed ID: 24045179 [TBL] [Abstract][Full Text] [Related]
22. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Ling YH; Li T; Yuan Z; Haigentz M; Weber TK; Perez-Soler R Mol Pharmacol; 2007 Aug; 72(2):248-58. PubMed ID: 17456787 [TBL] [Abstract][Full Text] [Related]
23. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p. Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891 [TBL] [Abstract][Full Text] [Related]
24. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Shapiro GI; Park JE; Edwards CD; Mao L; Merlo A; Sidransky D; Ewen ME; Rollins BJ Cancer Res; 1995 Dec; 55(24):6200-9. PubMed ID: 8521414 [TBL] [Abstract][Full Text] [Related]
25. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma. Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375 [TBL] [Abstract][Full Text] [Related]
26. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158 [TBL] [Abstract][Full Text] [Related]
27. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. McClendon AK; Dean JL; Rivadeneira DB; Yu JE; Reed CA; Gao E; Farber JL; Force T; Koch WJ; Knudsen ES Cell Cycle; 2012 Jul; 11(14):2747-55. PubMed ID: 22751436 [TBL] [Abstract][Full Text] [Related]
28. Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms. Olmez I; Brenneman B; Xiao A; Serbulea V; Benamar M; Zhang Y; Manigat L; Abbas T; Lee J; Nakano I; Godlewski J; Bronisz A; Abounader R; Leitinger N; Purow B Clin Cancer Res; 2017 Nov; 23(22):6958-6968. PubMed ID: 28814434 [No Abstract] [Full Text] [Related]
29. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells. Cao Y; Li X; Kong S; Shang S; Qi Y J Cell Mol Med; 2020 May; 24(9):5135-5145. PubMed ID: 32277580 [TBL] [Abstract][Full Text] [Related]
30. CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Francis AM; Alexander A; Liu Y; Vijayaraghavan S; Low KH; Yang D; Bui T; Somaiah N; Ravi V; Keyomarsi K; Hunt KK Mol Cancer Ther; 2017 Sep; 16(9):1751-1764. PubMed ID: 28619757 [TBL] [Abstract][Full Text] [Related]
31. Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells. Chen L; Pan J Br J Pharmacol; 2017 Aug; 174(15):2427-2443. PubMed ID: 28444744 [TBL] [Abstract][Full Text] [Related]
32. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Yang L; Mashima T; Sato S; Mochizuki M; Sakamoto H; Yamori T; Oh-Hara T; Tsuruo T Cancer Res; 2003 Feb; 63(4):831-7. PubMed ID: 12591734 [TBL] [Abstract][Full Text] [Related]
33. Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in Shi R; Li M; Raghavan V; Tam S; Cabanero M; Pham NA; Shepherd FA; Moghal N; Tsao MS Clin Cancer Res; 2018 Dec; 24(23):5990-6000. PubMed ID: 30093452 [TBL] [Abstract][Full Text] [Related]
34. Artocarpin, an isoprenyl flavonoid, induces p53-dependent or independent apoptosis via ROS-mediated MAPKs and Akt activation in non-small cell lung cancer cells. Tsai MH; Liu JF; Chiang YC; Hu SC; Hsu LF; Lin YC; Lin ZC; Lee HC; Chen MC; Huang CL; Lee CW Oncotarget; 2017 Apr; 8(17):28342-28358. PubMed ID: 28423703 [TBL] [Abstract][Full Text] [Related]
35. Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide. Bartling B; Lewensohn R; Zhivotovsky B Exp Cell Res; 2004 Aug; 298(1):83-95. PubMed ID: 15242764 [TBL] [Abstract][Full Text] [Related]
36. XIAP inhibits mature Smac-induced apoptosis by degrading it through ubiquitination in NSCLC. Qin S; Yang C; Zhang B; Li X; Sun X; Li G; Zhang J; Xiao G; Gao X; Huang G; Wang P; Ren H Int J Oncol; 2016 Oct; 49(4):1289-96. PubMed ID: 27498621 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Hashizume R; Zhang A; Mueller S; Prados MD; Lulla RR; Goldman S; Saratsis AM; Mazar AP; Stegh AH; Cheng SY; Horbinski C; Haas-Kogan DA; Sarkaria JN; Waldman T; James CD Neuro Oncol; 2016 Nov; 18(11):1519-1528. PubMed ID: 27370397 [TBL] [Abstract][Full Text] [Related]
38. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611 [TBL] [Abstract][Full Text] [Related]
39. eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer. Kong T; Xue Y; Cencic R; Zhu X; Monast A; Fu Z; Pilon V; Sangwan V; Guiot MC; Foulkes WD; Porco JA; Park M; Pelletier J; Huang S Mol Cancer Ther; 2019 Nov; 18(11):2158-2170. PubMed ID: 31395685 [TBL] [Abstract][Full Text] [Related]